Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial in 22 Countries

Together, they offer a comprehensive solution for enhanced sexual performance and satisfaction. Uses of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Improvement of overall sexual performance and satisfaction Benefits of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Dual-action formula for treating ED and PE Enhances erectile function and control over ejaculation Mechanism of Action of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Tadalafil: This component works by inhibiting the enzyme phosphodiesterase type 5 (PDE5), which promotes the relaxation of blood vessels in the penis, enhancing blood flow and facilitating the achievement and maintenance of an erection during sexual stimulation. Dapoxetine: This component functions as a selective serotonin reuptake inhibitor (SSRI), increasing the level of serotonin in the nervous system. This action delays the ejaculation reflex, helping to extend the duration of sexual intercourse and improve control over ejaculation. Beside this well also export in other countries Skip to content Sildenafil Citrate + Dapoxetine HCl DC Grade Enquire Now Want to develop a new product? Octavius Pharma has developed DC granules of Sildenafil Citrate + Dapoxetine HCl for making Sildenafil Citrate + Dapoxetine HCl plain tablets. Product has been developed to produce uniform particles that help give a better flow-ability in a way that facilitates tablet compression maintain content uniformity and designed to release drug within 15 minutes. Finished tablet qualitative composition and dissolution profile is in line with the Innovator “Priligy” throughout shelf life, Granules complies as per IH specification. Sildenafil Citrate + Dapoxetine HCl: Sildenafil+Dapoxetine is used in the treatment of premature ejaculation. It is a combination of two medicines, Sildenafil is a phosphodiesterase type 5 (PDE 5) inhibitor which works by increasing blood flow to the penis during sexual stimulation and enables its erection following sexual stimulation. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) which increases the level of serotonin in nerves to increase the time taken to ejaculate and improve control over ejaculation. For inquiries and collaboration opportunities, reach out to us today! Your gateway to innovative healthcare solutions awaits!

When Not to Use?

Japan and South Korea have demonstrated mature market characteristics with 62% and 58% insurance coverage rates respectively for PE therapies. North America represented 28.6% of the global market during 2025, driven by advanced healthcare infrastructure, high patient awareness levels, and robust coverage under insurance plans including Medicare, Medicaid, and private insurers. The United States market was valued at approximately $1.03 billion in 2025, with 67% of treatment-seeking patients accessing care through licensed therapists and urologists rather than self-medication approaches. The FDA approval of dapoxetine in 2012 catalyzed market expansion, and subsequent approvals of combination therapies and novel delivery mechanisms have sustained growth momentum. Canada and Mexico collectively contribute 18% of North American revenues, with Mexico experiencing accelerated growth due to expansion of private dermatology and urology clinics in major cities including Mexico City, Guadalajara, and Monterrey.

Chemical Formula

Telemedicine penetration in North America reached 34% of all sexual health consultations by 2025, with platforms like GoodRx and Amazon Pharmacy facilitating accessibility. Europe contributed 22.4% to global revenues in 2025, characterized by mature healthcare systems and robust regulatory frameworks across Germany, United Kingdom, France, and Spain. The European Medicines Agency's stringent approval processes have established high therapeutic standards, with dapoxetine and fluoxetine formulations commanding premium pricing relative to generic alternatives. Germany's market grew at 8.1% CAGR through 2025, while the United Kingdom maintained steady demand driven by NHS referrals and private clinic networks. The long-term care integration of sexual dysfunction screening into routine primary care has improved diagnosis rates by 19% since 2020. Segments - by Treatment Type (Pharmaceutical, Behavioral Therapy, Devices), Distribution Channel (Hospitals, Clinics, Online Pharmacies, Retail Pharmacies), End-User (Men, Healthcare Providers), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2025-2033 Global market valued at $4.2 billion in 2025 Expected to reach $8.9 billion by 2033 at CAGR of 9.8% Pharmaceutical treatment held largest share at 58.4% Asia Pacific dominated with 35.2% revenue share Key drivers: increasing prevalence of PE, growing awareness, rising healthcare expenditure, expanded access to telemedicine Pfizer Inc. led competitive landscape with dapoxetine formulations Report spans 2025 to 2033 with 251 pages of comprehensive analysis The global premature ejaculation treatment market is valued at $4.2 billion in 2025 and is projected to reach $8.9 billion by 2033, representing a 9.8% CAGR throughout the forecast period. Premature ejaculation, characterized by persistent or recurrent ejaculation during partnered sexual activity with minimal stimulation before the individual wishes it, affects approximately 20% to 30% of men globally, driving substantial demand for efficacious treatment modalities.

Product	Dosage	Quantity + Bonus	Price
Cialis Soft Tabs	20mg	10 Pills	39.03€ 37.17€	Buy
Priligy Generic Dapoxetine	60mg	20 + 4 Pills	77.31€ 73.63€	Buy
Cialis Professional	20mg	60 + 2 Pills	183.83€ 175.08€	Buy
Cialis Soft Tabs	20mg	120 + 6 Pills	248.64€ 236.80€	Buy
Priligy Generic Dapoxetine	60mg	90 + 10 Pills	265.64€ 252.99€	Buy
Viagra Professional	100mg	120 + 4 Pills	262.83€ 250.31€	Buy
Priligy Generic Dapoxetine	60mg	180 + 10 Pills	494.76€ 471.20€	Buy
Cialis Generic	2.5mg	60 + 4 Pills	83.43€ 79.46€	Buy
Levitra Original	20mg	92 + 4 Pills	406.22€ 386.88€	Buy
Priligy Generic Dapoxetine	60mg	30 + 6 Pills	106.65€ 101.57€	Buy
Priligy Generic Dapoxetine	60mg	10 Pills	47.63€ 45.36€	Buy
Levitra Professional	20mg	120 + 4 Pills	348.44€ 331.85€	Buy
Priligy Generic Dapoxetine	60mg	60 + 8 Pills	183.06€ 174.34€	Buy
Kamagra Polo	100mg	32 Pills	125.88€ 119.89€	Buy
Priligy Generic Dapoxetine	60mg	120 + 10 Pills	341.26€ 325.01€	Buy
Kamagra Gold	100 mg	180 + 6 Pills	436.79€ 415.99€	Buy

The market encompasses three primary treatment avenues: pharmaceutical interventions including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and the US FDA-approved dapoxetine; behavioral therapies including the start-stop technique and the squeeze technique developed by sex therapists and psychologists; and emerging devices such as topical anesthetics and novel mechanical solutions. Prevalence estimates indicate that PE-related consultations have surged by 42% since 2020, particularly among younger demographics aged 18-35 seeking clinical guidance.

• Dapoxetine's popularity increased among young Spanish men.
• The drug is often used with counseling for better results.
• Spain has educational campaigns about premature ejaculation treatments.
• Dapoxetine's cost-effectiveness makes it attractive in Spain.
• Many online pharmacies sell dapoxetine with a prescription.
• Dapoxetine is considered a first-line treatment for PE in Spain.
• Patients should report adverse effects to their doctor promptly.

The expansion of telemedicine platforms and digital health solutions has significantly lowered barriers to access, enabling men to obtain treatments without stigma-related concerns. Additionally, increasing healthcare spending across developed and emerging markets, coupled with growing insurance coverage for sexual dysfunction therapies, has expanded patient reach.

How Dapoxetine Work

Depression and anxiety

Major pharmaceutical corporations including Pfizer Inc., Eli Lilly and Company, and sildenafil and dapoxetine Bayer AG have substantially invested in PE treatment development, resulting in multiple FDA-cleared and EMA-approved formulations.

Contact now

Major pharmaceutical corporations including Pfizer Inc., Eli Lilly and Company, and sildenafil and dapoxetine Bayer AG have substantially invested in PE treatment development, resulting in multiple FDA-cleared and EMA-approved formulations. The integration of behavioral therapy with pharmaceutical treatments has emerged as the gold standard, enhancing therapeutic efficacy and patient satisfaction metrics by approximately 35% compared to monotherapy approaches. Controlled-release drug delivery innovations are enabling more sustained and predictable therapeutic outcomes, particularly for topical dapoxetine formulations that require consistent pharmacokinetic profiles. Government initiatives promoting sexual health awareness in countries like India, Brazil, and South Korea have further catalyzed market expansion. This analysis is based on primary and secondary research conducted through Q4 2025, with data verified as of May 2026.

Terms related to this study

Asia Pacific emerged as the dominant region, commanding $1.48 billion in market valuation during 2025, representing 35.2% of global revenue. This regional dominance stems from the convergence of multiple factors: rapidly increasing male population of reproductive age, escalating healthcare expenditure in countries including China, India, and Japan, and the emergence of specialized clinics dedicated to men's sexual health in urban centers. India, housing approximately 1.4 billion people with an estimated 28% PE prevalence rate among adult males, represents the single largest patient population globally. The proliferation of digital health platforms in India, including Practo and DocsApp, has enabled consultations reaching previously underserved rural populations. China's market grew at 11.2% CAGR from 2020 to 2025, driven by increasing acceptance of sexual dysfunction treatment in traditionally conservative societies and the expansion of pharmaceutical manufacturing capabilities for SSRIs and dapoxetine formulations. The integration of behavioral therapy with pharmaceutical treatments has emerged as the gold standard, enhancing therapeutic efficacy and patient satisfaction metrics by approximately 35% compared to monotherapy approaches. Controlled-release drug delivery innovations are enabling more sustained and predictable therapeutic outcomes, particularly for topical dapoxetine formulations that require consistent pharmacokinetic profiles. Government initiatives promoting sexual health awareness in countries like India, Brazil, and South Korea have further catalyzed market expansion.

Company	Market Share (%)	Main Competitors	Notes
Johnson & Johnson	45%	Generic manufacturers	Leading brand, high recognition
Local Pharma Co.	20%	Other generics	Gaining popularity
International Generics Firms	25%	Various	Competitive pricing

This analysis is based on primary and secondary research conducted through Q4 2025, with data verified as of May 2026. Asia Pacific emerged as the dominant region, commanding $1.48 billion in market valuation during 2025, representing 35.2% of global revenue. This regional dominance stems from the convergence of multiple factors: rapidly increasing male population of reproductive age, escalating healthcare expenditure in countries including China, India, and Japan, and the emergence of specialized clinics dedicated to men's sexual health in urban centers. India, housing approximately 1.4 billion people with an estimated 28% PE prevalence rate among adult males, represents the single largest patient population globally. The proliferation of digital health platforms in India, including Practo and DocsApp, has enabled consultations reaching previously underserved rural populations.

Storage and disposal

Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) which increases the level of serotonin in nerves to increase the time taken to ejaculate and improve control over ejaculation. For inquiries and collaboration opportunities, reach out to us today! Your gateway to innovative healthcare solutions awaits! Segments - by Treatment Type (Pharmaceutical, Behavioral Therapy, Devices), Distribution Channel (Hospitals, Clinics, Online Pharmacies, Retail Pharmacies), End-User (Men, Healthcare Providers), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2025-2033 Global market valued at $4.2 billion in 2025 Expected to reach $8.9 billion by 2033 at CAGR of 9.8% Pharmaceutical treatment held largest share at 58.4% Asia Pacific dominated with 35.2% revenue share Key drivers: increasing prevalence of PE, growing awareness, rising healthcare expenditure, expanded access to telemedicine Pfizer Inc. led competitive landscape with dapoxetine formulations Report spans 2025 to 2033 with 251 pages of comprehensive analysis The global premature ejaculation treatment market is valued at $4.2 billion in 2025 and is projected to reach $8.9 billion by 2033, representing a 9.8% CAGR throughout the forecast period.

What is the study measuring?

Premature ejaculation, characterized by persistent or recurrent ejaculation during partnered sexual activity with minimal stimulation before the individual wishes it, affects approximately 20% to 30% of men globally, driving substantial demand for efficacious treatment modalities. The market encompasses three primary treatment avenues: pharmaceutical interventions including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and the US FDA-approved dapoxetine; behavioral therapies including the start-stop technique and the squeeze technique developed by sex therapists and psychologists; and emerging devices such as topical anesthetics and novel mechanical solutions. Prevalence estimates indicate that PE-related consultations have surged by 42% since 2020, particularly among younger demographics aged 18-35 seeking clinical guidance. The expansion of telemedicine platforms and digital health solutions has significantly lowered barriers to access, enabling men to obtain treatments without stigma-related concerns. Additionally, increasing healthcare spending across developed and emerging markets, coupled with growing insurance coverage for sexual dysfunction therapies, has expanded patient reach. China's market grew at 11.2% CAGR from 2020 to 2025, driven by increasing acceptance of sexual dysfunction treatment in traditionally conservative societies and the expansion of pharmaceutical manufacturing capabilities for SSRIs and dapoxetine formulations. Japan and South Korea have demonstrated mature market characteristics with 62% and 58% insurance coverage rates respectively for PE therapies. North America represented 28.6% of the global market during 2025, driven by advanced healthcare infrastructure, high patient awareness levels, and robust coverage under insurance plans including Medicare, Medicaid, and private insurers.

About dapoxetine

Brochure PRODUCT LIST OF PHARMA JITAI

The United States market was valued at approximately $1.03 billion in 2025, with 67% of treatment-seeking patients accessing care through licensed therapists and urologists rather than self-medication approaches. The FDA approval of dapoxetine in 2012 catalyzed market expansion, and subsequent approvals of combination therapies and novel delivery mechanisms have sustained growth momentum. Canada and Mexico collectively contribute 18% of North American revenues, with Mexico experiencing accelerated growth due to expansion of private dermatology and urology clinics in major cities including Mexico City, Guadalajara, and Monterrey. Telemedicine penetration in North America reached 34% of all sexual health consultations by 2025, with platforms like GoodRx and Amazon Pharmacy facilitating accessibility.

• Buying dapoxetine without a prescription in Spain is generally discouraged.
• Spain's healthcare system regulates access to dapoxetine through doctors.
• Clinical trials in Spain confirmed dapoxetine's effectiveness for PE.
• Patients should follow prescribed dosage instructions carefully.
• Drug interactions with dapoxetine may include other antidepressants.
• Dapoxetine does not cause a long-lasting effect after stopping.
• The medication is often well-tolerated in Spanish patients.

Europe contributed 22.4% to global revenues in 2025, characterized by mature healthcare systems and robust regulatory frameworks across Germany, United Kingdom, France, and Spain.

• Dapoxetine was introduced to the Spanish market after regulatory approval.
• It can enhance sexual satisfaction by delaying ejaculation.
• Dapoxetine has a rapid onset of action, typically within hours.
• The pharmacy distribution of dapoxetine in Spain is widespread.
• Dapoxetine prescriptions in Spain increased in recent years.
• It is considered a safe option when used responsibly.
• Patients are advised to avoid alcohol when taking dapoxetine.

The European Medicines Agency's stringent approval processes have established high therapeutic standards, with dapoxetine and fluoxetine formulations commanding premium pricing relative to generic alternatives. Germany's market grew at 8.1% CAGR through 2025, while the United Kingdom maintained steady demand driven by NHS referrals and private clinic networks. The long-term care integration of sexual dysfunction screening into routine primary care has improved diagnosis rates by 19% since 2020. Latin America captured 10.2% of global market share, with Brazil, Argentina, and Colombia leading regional expansion through growing middle-class populations seeking premium healthcare services. The Middle East and Africa region represented 3.6% of global revenues, though demonstrating the fastest growth trajectory at 12.4% CAGR due to increasing healthcare infrastructure investments and gradually improving cultural attitudes toward sexual health treatment. Epidemiological studies reveal that premature ejaculation affects 20% to 30% of men globally, with prevalence concentrating among younger demographics aged 18-40 experiencing elevated psychological stress.

Study record dates

Latin America captured 10.2% of global market share, with Brazil, Argentina, and Colombia leading regional expansion through growing middle-class populations seeking premium healthcare services. The Middle East and Africa region represented 3.6% of global revenues, though demonstrating the fastest growth trajectory at 12.4% CAGR due to increasing healthcare infrastructure investments and gradually improving cultural attitudes toward sexual health treatment. Epidemiological studies reveal that premature ejaculation affects 20% to 30% of men globally, with prevalence concentrating among younger demographics aged 18-40 experiencing elevated psychological stress. Clinical recognition has intensified following the publication of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) revisions categorizing PE as a clinically significant condition requiring professional intervention. Major healthcare systems including Mayo Clinic, Cleveland Clinic, and Kaiser Permanente have established dedicated sexual medicine departments addressing PE through comprehensive diagnostic protocols.

Product TADALAFIL

The American Urological Association and European Association of Urology have published evidence-based treatment guidelines emphasizing multimodal approaches combining pharmaceutical, behavioral, and device-based interventions. Increased diagnostic screening in primary care settings has expanded patient identification by 41% since 2020, generating substantial downstream demand for therapeutic options. Insurance companies have responded by expanding coverage policies, with 73% of major US insurers now covering dapoxetine prescriptions under pharmacy benefits. Clinical recognition has intensified following the publication of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) revisions categorizing PE as a clinically significant condition requiring professional intervention. Major healthcare systems including Mayo Clinic, Cleveland Clinic, and Kaiser Permanente have established dedicated sexual medicine departments addressing PE through comprehensive diagnostic protocols. The American Urological Association and European Association of Urology have published evidence-based treatment guidelines emphasizing multimodal approaches combining pharmaceutical, behavioral, and device-based interventions. Increased diagnostic screening in primary care settings has expanded patient identification by 41% since 2020, generating substantial downstream demand for therapeutic options.

Althernative Medicine

Together, they offer a comprehensive solution for enhanced sexual performance and satisfaction. Uses of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Improvement of overall sexual performance and satisfaction Benefits of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Dual-action formula for treating ED and PE Enhances erectile function and control over ejaculation Mechanism of Action of Extra Super Tadarise Tadalafil and Dapoxetine Tablets: Tadalafil: This component works by inhibiting the enzyme phosphodiesterase type 5 (PDE5), which promotes the relaxation of blood vessels in the penis, enhancing blood flow and facilitating the achievement and maintenance of an erection during sexual stimulation. Dapoxetine: This component functions as a selective serotonin reuptake inhibitor (SSRI), increasing the level of serotonin in the nervous system. This action delays the ejaculation reflex, helping to extend the duration of sexual intercourse and improve control over ejaculation. Beside this well also export in other countries Skip to content Sildenafil Citrate + Dapoxetine HCl DC Grade Enquire Now Want to develop a new product?

Product Vardenafil Hydrochloride

Octavius Pharma has developed DC granules of Sildenafil Citrate + Dapoxetine HCl for making Sildenafil Citrate + Dapoxetine HCl plain tablets. Product has been developed to produce uniform particles that help give a better flow-ability in a way that facilitates tablet compression maintain content uniformity and designed to release drug within 15 minutes. Finished tablet qualitative composition and dissolution profile is in line with the Innovator “Priligy” throughout shelf life, Granules complies as per IH specification. Sildenafil Citrate + Dapoxetine HCl: Sildenafil+Dapoxetine is used in the treatment of premature ejaculation. It is a combination of two medicines, Sildenafil is a phosphodiesterase type 5 (PDE 5) inhibitor which works by increasing blood flow to the penis during sexual stimulation and enables its erection following sexual stimulation. Insurance companies have responded by expanding coverage policies, with 73% of major US insurers now covering dapoxetine prescriptions under pharmacy benefits.